Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia

Blood

Volumn 94, Issue 2, 1999, Pages 803-807

  Larson, Richard A ^a   Wang, Yunxia ^b   Banerjee, Mekhala ^b   Wiemels, Joseph ^b   Hartford, Christine ^b   Le Beau, Michelle M ^b   Smith, Martyn T ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; GYRASE INHIBITOR; OXIDOREDUCTASE; QUINONE DERIVATIVE; QUINONE OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR PROTEIN;

ARTICLE; BLOOD TOXICITY; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; POINT MUTATION; PRIORITY JOURNAL; ALLELE; CHEMICALLY INDUCED DISORDER; CHROMOSOME 5; CHROMOSOME 7; CODON; ENZYMOLOGY; ETHNIC GROUP; GENE FREQUENCY; GENETICS; GENOTYPE; KARYOTYPING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RACE; RADIATION INJURY; RADIOTHERAPY; SECOND CANCER;

ALLELES; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; CODON; CONTINENTAL POPULATION GROUPS; DNA MUTATIONAL ANALYSIS; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MYELODYSPLASTIC SYNDROMES; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM PROTEINS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RADIOTHERAPY;

EID: 0033564977     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.2.803     Document Type: Article

References (32)

1. Thirman MJ, Larson RA: Therapy-related myeloid leukemia. Hematol Oncol Clinics North Am 10:293, 1996
2. Vigliani EC, Saita G: Benzene and leukemia. N Engl J Med 271:872, 1954
3. Laskin S, Goldstein BD: Benzene toxicity: A critical evaluation. J Toxicol Environ Health 2:1, 1977
4. Rinsky RA, Smith AB, Hornung RF, Filloon TG, Young RJ, Okun AH, Landrigan PJ: Benzene and leukemia. An epidemiologic risk assessment. N Engl J Med 316:1044, 1987
5. Aksoy M: Benzene Carcinogenicity. Boca Raton, FL, CRC, 1988, p 113
6. Hayes RB, Yin SN, Dosemeci M, Li GL, Wacholder S, Travis LB, Li CY, Rothman N, Hoover RN, Linet MS: Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. J Natl Cancer Inst 89:1065, 1997
7. Rothman N, Li GL, Dosemeci M. Bechtold WE, Marti GE, Wang YZ, Linet M, Xi U, Lu W, Smith MT, Titenko-Holland N, Zhang LP, Blot W, Yin SN, Hayes RB-. Hematotoxicity among Chinese workers heavily exposed to benzene. Am J Ind Med 29:236, 1996
8. Boddy AV, Ratain MJ: Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res 3:1025, 1997
9. 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 57:2839, 1997
10. Eastmond DA, Smith MT, Irons RD: An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure. Toxicol Appl Pharmacol 91:85, 1987
11. Smith MT, Yager JW, Steinmetz KL, Eastmond DA: Peroxidase-dependent metabolism of benzene's phenolic metabolites and its potential role in benzene toxicity and carcinogenicity. Environ Health Perspect 82:23, 1989
12. Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW: Bioactivation of quinones by DT-diaphorase. Molecular, biochemical and chemical studies. Oncol Res 6:493, 1994
13. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, Rodd D: Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. Cancer Res 54:3196, 1996
14. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T: DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 56:2823, 1996
15. Hu LT, Stamberg J, Pan SS: The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C. Cancer Res 56:5253, 1996
16. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH: Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 5:199, 1995
17. Wiencke JK, Spitz MR, McMillan A, Kelsey KT: Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Ca Epidemiol Biol Prevent 6:87, 1997
18. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer THW, Danenberg PV, Ross D, Gibson NW: NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells; characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52:797, 1992
19. Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, Rauth AM: A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): Relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 74:995, 1996
20. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D: Characterization of a polymorphism in NADP(H): quinone oxidoreductase (DT diaphorase). Br J Cancer 75:69, 1997
21. Traver RD, Rothman N, Smith MT, Yin SY, Hayes RB, Li GL, Franklin WA, Ross D: Incidence of a polymorphism in NAD(P)H: quinone oxidoreductase (NQO1). Proc Am Assoc Cancer Res 37:278, 1996 (abstr 1894)
22. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo Z-F, Spitz MR, Wang M, Xu X, Lee B-K, Schwartz BS, Wiencke JK: Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 76:852, 1997
23. Larson RA, Le Beau MM, Vardiman JW, Rowley JD: Myeloid leukemia after hematotoxins. Environ Health Perspect 104:1303, 1996 (suppl 6)
24. Joventino LP, Stock W, Lane NJ, Daly KM, Mick R, Le Beau MM, Larson RA: Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia 9:433, 1995
25. Fourth International Workshop on Chromosomes in Leukemia, 1982: The correlation of karyotype and occupational exposure to potential mutagenic/carcinogenic agents in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 11:326, 1984
26. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosome no. 5 and 7. J Clin Oncol 4:325, 1986
27. Irons RD, Stillman WS: The process of leukemogenesis. Environ Health Perspect 104:1239, 1996 (suppl 6)
28. Pedersen-Bjergaard J, Rowley JD: The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83:2780, 1994
29. Pedersen-Bjergaard J, Pedersen M. Roulston D, Philip P: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542, 1995
30. Le Beau MM: Cytogenetic analysis of hematological malignancies, in Barch MJ (ed): The ACT Cytogenetic Laboratory Manual (ed 2). New York, NY, Raven, 1991, p 395
31. Tosato G: Generation of Epstein-Barr virus (EBV)-immortalized B cell lines, in Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds): Current Protocols in Immunology. New York, NY, Wiley, 1991, p 7.22.1
32. Eickelmann P, Schulz WA, Rohde D, Schmitz-Drager B, Sies H: Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe Seyler 375:439, 1994